Your browser doesn't support javascript.
loading
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Giesen, Nicola; Chatterjee, Manik; Scheid, Christof; Poos, Alexandra M; Besemer, Britta; Miah, Kaya; Benner, Axel; Becker, Nicole; Moehler, Thomas; Metzler, Ivana; Khandanpour, Cyrus; Seidel-Glaetzer, Andrea; Trautmann-Grill, Karolin; Kortüm, K Martin; Müller-Tidow, Carsten; Mechtersheimer, Gunhild; Goeppert, Benjamin; Stenzinger, Albrecht; Weinhold, Niels; Goldschmidt, Hartmut; Weisel, Katja; Raab, Marc S.
Affiliation
  • Giesen N; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Chatterjee M; Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Scheid C; Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
  • Poos AM; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
  • Besemer B; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Miah K; Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tübingen, Tübingen, Germany.
  • Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Becker N; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Moehler T; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Metzler I; IQVIA, Frankfurt, Germany.
  • Khandanpour C; Hematology and Oncology, Frankfurt University Medical Center, Frankfurt, Germany.
  • Seidel-Glaetzer A; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
  • Trautmann-Grill K; University Medical Center Schleswig-Holstein Campus Lϋbeck, University of Lϋbeck, Lϋbeck, Germany.
  • Kortüm KM; Coordinating Centre for Clinical Trials (KKS), Heidelberg University, Heidelberg, Germany.
  • Müller-Tidow C; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Mechtersheimer G; Department of Medicine II, University Hospital of Würzburg, Würzburg, Germany.
  • Goeppert B; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Stenzinger A; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Weinhold N; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Goldschmidt H; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Weisel K; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Raab MS; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Blood ; 141(14): 1685-1690, 2023 04 06.
Article in En | MEDLINE | ID: mdl-36608320
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2023 Document type: Article Affiliation country: Country of publication: